Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: Findings from the SMART cohort.


Journal

Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645

Informations de publication

Date de publication:
08 2019
Historique:
received: 25 01 2019
revised: 17 04 2019
accepted: 30 04 2019
pubmed: 8 5 2019
medline: 17 9 2020
entrez: 8 5 2019
Statut: ppublish

Résumé

To quantify the magnitude and specific contributions of known cardiovascular risk factors leading to higher cardiovascular risk and all-cause mortality caused by type 2 diabetes (T2D). Mediation analysis was performed to assess the relative contributions of known classical risk factors for vascular disease in T2D (insulin resistance, systolic blood pressure, renal function, LDL-cholesterol, triglycerides and micro-albuminuria), and what proportion of the effect of T2D on cardiovascular events and all-cause mortality these factors mediate in the Second Manifestations of ARTerial disease (SMART) cohort consisting of 1910 T2D patients. Only 35% (95% CI 15-71%) of the excess cardiovascular risk caused by T2D is mediated by the classical cardiovascular risk factors. The largest mediated effect was through insulin resistance [proportion of mediated effect (PME) 18%, 95% CI 3-37%], followed by elevated triglycerides (PME 8%, 95% CI 4-14%) and micro-albuminuria (PME 7%, 95% CI 3-17%). Only 42% (95% CI 18-73%) of the excess mortality risk was mediated by the classical risk factors considered. The largest mediated effect was by micro-albuminuria (PME 18%, 95% CI 10-29%) followed by insulin resistance (PME 15%, 95% CI 1-33%). A substantial amount of the increased cardiovascular risk and all-cause mortality caused by T2D cannot be explained by traditional vascular risk factors. Future research should focus on identifying non-classical pathways that might further explain the increased cardiovascular and mortality risk caused by T2D.

Identifiants

pubmed: 31062479
doi: 10.1111/dom.13759
pmc: PMC6767388
doi:

Substances chimiques

Cholesterol, LDL 0
Triglycerides 0

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1935-1943

Investigateurs

R van Petersen (R)
B G F Dinther (BGF)
A Algra (A)
Y van der Graaf (Y)
D E Grobbee (DE)
G E H M Rutten (GEHM)
F L J Visseren (FLJ)
G J de Borst (GJ)
L J Kappelle (LJ)
T Leiner (T)
H M Nathoe (HM)

Informations de copyright

© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Références

Eur Heart J. 2008 Dec;29(24):2959-71
pubmed: 18775919
Am J Epidemiol. 2012 Aug 1;176(3):190-5
pubmed: 22781427
N Engl J Med. 1997 Apr 3;336(14):973-9
pubmed: 9077376
BMJ. 2013 Jul 29;347:f4533
pubmed: 23900314
Diabetes Care. 1999 Apr;22(4):562-8
pubmed: 10189532
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
Am J Epidemiol. 2014 Feb 15;179(4):513-8
pubmed: 24264291
Diabetes. 1998 Feb;47(2):290-3
pubmed: 9519730
Diabetes Obes Metab. 2019 Aug;21(8):1935-1943
pubmed: 31062479
Am J Cardiol. 1999 Jul 8;84(1A):37J-41J
pubmed: 10418858
Diabetes Obes Metab. 2016 Nov;18(11):1120-1127
pubmed: 27337598
Diabetologia. 2008 Apr;51(4):527-39
pubmed: 18239908
Lancet Diabetes Endocrinol. 2015 May;3(5):356-66
pubmed: 25791290
World J Cardiol. 2012 Apr 26;4(4):90-102
pubmed: 22558488
Metabolism. 2005 Mar;54(3):345-50
pubmed: 15736112
Circulation. 1998 Aug 25;98(8):731-3
pubmed: 9727541
Int J Obes (Lond). 2008 May;32 Suppl 2:S21-4
pubmed: 18469836
Circulation. 2005 Nov 15;112(20):3066-72
pubmed: 16275870
Diabetes Care. 2006 Feb;29(2):329-33
pubmed: 16443882
Clin Biochem. 2004 Sep;37(9):785-90
pubmed: 15329317
Heart. 2001 Jan;85(1):87-91
pubmed: 11119472
Diabetes Care. 1999 Sep;22(9):1543-8
pubmed: 10480523
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Endocr Rev. 2004 Feb;25(1):153-75
pubmed: 14769830
Ann Intern Med. 2000 Jul 18;133(2):81-91
pubmed: 10896647
Am J Med. 2006 Oct;119(10):812-9
pubmed: 17000207
N Engl J Med. 2003 Jan 30;348(5):383-93
pubmed: 12556541
Arch Intern Med. 1997 Jul 14;157(13):1413-8
pubmed: 9224218
Diabetes Care. 2002 Jul;25(7):1135-41
pubmed: 12087010
Eur J Epidemiol. 1999 Oct;15(9):773-81
pubmed: 10608355

Auteurs

Shahnam Sharif (S)

Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

Rolf H H Groenwold (RHH)

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

Yolanda van der Graaf (Y)

Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

Gijs F N Berkelmans (GFN)

Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

Maarten J Cramer (MJ)

Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Frank L J Visseren (FLJ)

Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

Jan Westerink (J)

Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH